Biocon Biologics Inks Deal with Sandoz for Japan
Biocon Biologics has partnered with Sandoz to exclusively market Adalimumab BS for subcutaneous injection, indicated for immune-related diseases, in Japan.
Photograph: Kind courtesy Biocon Biologics/Facebook
New Delhi, Dec 22 (PTI) Biocon Biologics on Friday said it has given exclusive rights to sell and distribute a drug, indicated for the treatment of immune-related diseases, in Japan.
The company has signed a distribution agreement with Sandoz, granting the company the exclusive rights to promote, sell and distribute Adalimumab BS for subcutaneous injection in Japan, Biocon Biologics said in a statement.
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Biocon Biologics is a subsidiary of Bengaluru-headquartered Biocon Ltd.
The company has signed a distribution agreement with Sandoz, granting the company the exclusive rights to promote, sell and distribute Adalimumab BS for subcutaneous injection in Japan, Biocon Biologics said in a statement.
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Biocon Biologics is a subsidiary of Bengaluru-headquartered Biocon Ltd.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Enbee Trade & Fi
- 0.53 ( -3.64)
- 71066283
- Shangar Decor
- 0.53 (+ 3.92)
- 41511883
- Jaiprakash Power Ven
- 23.64 (+ 2.69)
- 41086674
- Vodafone Idea L
- 7.16 ( -2.45)
- 35442008
- RattanIndia Power
- 16.14 ( -0.55)
- 29828841
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback